Macitentan Group — Competitive Intelligence Brief

Macitentan Group (Macitentan Group) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual endothelin receptor antagonist. Area: Cardiovascular.

phase 3 Dual endothelin receptor antagonist ETA and ETB receptors Cardiovascular Small molecule

Target snapshot

Macitentan Group (Macitentan Group) — University of Giessen. Macitentan is a dual endothelin receptor antagonist that blocks both ETA and ETB receptors to reduce pulmonary vascular resistance and improve exercise capacity in pulmonary arterial hypertension.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Macitentan Group TARGET	Macitentan Group	University of Giessen	phase 3	Dual endothelin receptor antagonist	ETA and ETB receptors
Macitentan Tablets	Macitentan Tablets	Dr Sudarshan Rajagopal	phase 3	Endothelin receptor antagonist	ETA and ETB receptors
macitentan (ACT-064992)	macitentan (ACT-064992)	Actelion	phase 3	Endothelin receptor antagonist	ETA and ETB receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual endothelin receptor antagonist class)

1. University of Giessen · 1 drug in this class